GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation...Read more
Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Data to be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting Company to discuss...Read more
As lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR® platform In preclinical studies, APVO711 demonstrates dual anti-cancer functionality with broad solid...Read more
AVMAPKI plus FAKZYNJA to be commercially available by prescription as a convenient oral combination co-packaged together and will be known as “AVMAPKI FAKZYNJA CO-PACK” Accelerated approval, well ahead of the June 30, 2025 PDUFA action date, was based on the Phase 2 RAMP 201 study that...Read more
Meeting to Take Place on July 25, 2025 Meeting’s Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs GLEN ALLEN, Va., May 08, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company...Read more
Breakthrough Therapy Designation request based on veligrotug’s (i) consistent and robust improvement and resolution of diplopia in chronic TED, and (ii) rapid onset of proptosis response Veligrotug met all of its primary and secondary endpoints in the pivotal THRIVE and THRIVE-2 clinical...Read more
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Regencell Bioscience | 22.01 11.58 | $212.00 |
| Mettler-Toledo | 17.17 1.58 | $1,101.63 |
| Addus HomeCare | 12.66 12.91 | $110.70 |
| QuidelOrtho | 10.61 41.04 | $36.46 |
| Bio-Rad Laboratories | 8.47 3.64 | $241.02 |
| ICU Medical | 8.37 6.22 | $142.87 |
| Tempus AI | 6.46 10.99 | $65.22 |
| Aclarion | 6.10 813.33 | $6.85 |
| Zoetis | 5.70 3.65 | $161.69 |
| Prestige Healthcare | 5.63 6.92 | $87.04 |
| Waters | 5.42 1.57 | $350.88 |
| Nuvalent | 4.88 7.31 | $71.60 |
| Charles River Laboratories | 4.39 3.21 | $141.36 |
| Illumina | 4.29 5.62 | $80.64 |
| Revolution Medicines | 4.25 11.29 | $41.91 |
| Outset Medical | 4.14 35.26 | $15.88 |
| Teleflex | 4.10 3.36 | $126.18 |
| Mirum Pharmaceuticals | 4.02 9.75 | $45.24 |
| Company | Volume | Last Trade |
|---|---|---|
| Pfizer | 54,653,290 | $22.95 |
| NuCana | 42,322,176 | $0.10 |
| Novavax | 36,581,176 | $6.65 |
| Viatris | 29,887,663 | $9.09 |
| Recursion | 26,997,950 | $4.39 |
| Tempus AI | 24,647,333 | $65.22 |
| Bristol-Myers Squibb | 21,728,824 | $46.88 |
| Teva Pharmaceutical | 19,712,688 | $18.07 |
| ImmunityBio | 17,687,349 | $2.09 |
| Vor Bio | 16,358,029 | $0.16 |
| Iovance Biotherapeutics | 15,624,569 | $3.17 |
| ADMA Biologics | 14,021,342 | $21.20 |
| Oscar Health | 13,143,534 | $17.04 |
| Gilead Sciences | 12,438,226 | $98.16 |
| Novo Nordisk | 11,933,851 | $64.85 |
| Merck | 11,674,671 | $77.76 |
| Akebia Therapeutics | 10,580,116 | $2.62 |
| Esperion | 10,157,330 | $0.89 |
| PacBio | 9,804,394 | $1.20 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
